Kim Lorence H. sold $3.6M of RVMD (indirect holdings)
Kim Lorence H. sold 17,090 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $209.82 ($206.60–$212.27, $3.59M total) across 7 trades on 2026-09-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The complete exit of a director could be interpreted as a lack of confidence, potentially prompting short sellers.
Market read
Insider sell may influence short-term price action in RVMD.
What to watch
The 10b5-1 plan pre-scheduled the sale, reducing informational value of the transaction.
Background
SEC Form 4 filing discloses insider transactions; directors often use 10b5-1 plans for scheduled sales.
Ticker impact
Director Kim Lorence H. sold 17,090 shares for $3.6M via a 10b5-1 plan, reducing holdings to zero.
Potential short-term downside pressure as market digests the insider sell.
Director exits completely, large sell amount relative to typical insider trades, suggests lack of confidence.
Market effects
May raise concerns for biotech sector if insider sells increase.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Insider may have needed liquidity; sale does not necessarily reflect company fundamentals.
Key entities
- CompanyRevolution Medicines, Inc.
Biotech firm developing oncology therapies.
- InsiderKim Lorence H.
Director of Revolution Medicines.
